Reckitt Benckiser Group (LON:RKT) Releases Quarterly Earnings Results

Reckitt Benckiser Group (LON:RKT) released its quarterly earnings results on Thursday. The company reported GBX 349.70 ($4.51) earnings per share for the quarter, Digital Look Earnings reports. Reckitt Benckiser Group had a return on equity of 18.70% and a net margin of 10.78%.

Reckitt Benckiser Group Trading Up 1.9 %

Shares of RKT traded up GBX 102 ($1.31) during trading on Friday, reaching GBX 5,396 ($69.54). 27,337,354 shares of the company traded hands, compared to its average volume of 3,690,566. The stock has a 50-day simple moving average of GBX 5,116.55 and a 200-day simple moving average of GBX 4,831.42. The stock has a market cap of £36.81 billion, a PE ratio of 24.69, a price-to-earnings-growth ratio of 1.10 and a beta of 0.09. Reckitt Benckiser Group has a twelve month low of GBX 4,034 ($51.98) and a twelve month high of GBX 5,416 ($69.79). The company has a quick ratio of 0.46, a current ratio of 0.69 and a debt-to-equity ratio of 110.26.

Insider Transactions at Reckitt Benckiser Group

In related news, insider Shannon Eisenhardt sold 1,368 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of GBX 4,723 ($60.86), for a total transaction of £64,610.64 ($83,261.13). Company insiders own 0.05% of the company’s stock.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.